Shire zeroes in on Movetis to expand gastrointestinal pipeline


London/Turnhout – Speciality drug maker Shire plc has launched a EUR19-a-share offer for Belgian biotech company Movetis N.V., making the proposed acquisition worth EUR428m in cash. Shire said the deal would broaden its gastro­intestinal portfolio and expand its presence in Europe, where Movetis markets Resolor (prucalopride) for chronic constipation in women for whom laxatives fail to provide adequate relief. The proposed acquisition of Movetis fits into the company’s growth strategy of acquiring near-to-market or marketed products for specialty indications. By buying Movetis, Shire will add four gastrointestinal programs to its pipeline: two in the clinic, and two in preclinical testing. Movetis’ management have unanimously recommended the offer to shareholders, which represents a premium of 74% on stock prices before the bid was first announced in early August.

Brief and dynamic history

Movetis’ lead product Resolor has gained marketing approval in 30 European countries. The drug made its debut in Germany this January, and has since launched in the UK, where the health-cost regulator NICE recommended its use to the National Health Service on August 3rd. Staf Van Reet, board chairman of Movetis, described the Shire offer as “a further remarkable milestone in Movetis’ brief and dynamic history.” This includes an EUR85m offering in December 2009 and a single private EUR49m financing round in 2007. Movetis was spun out of Johnson & Johnson in 2006.



Brussels – Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m. The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms...



Leuven – Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S. ThromboGenics said it...



Amsterdam Molecular Therapeutics has announced a financial manoeuvre aimed at getting the biotech out of a hopeless situation. The assets and – more importantly – the liabilities of the drug developer will be acquired by a newly...



Amsterdam - Amsterdam Molecular Therapeutics has announced a financial manoeuvre which is aimed to get the biotech out of a dead end. The assets and – more importantly – the liabilities of the drug developer will be acquired by...



Glasgow/Leuven - With a little help from the EU, two biotech companies are banding together to develop the first stem cell therapy against rheumatoid arthritis. UK-based Sistemic will work with TiGenix to develop the Belgian's...



Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM...



Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from...



Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered into a financing of approximately €8.4 million by...



Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a...

Displaying results 1 to 10 out of 304

1-10 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • VITA 345.94 EUR7.03%
  • EVOTEC4.04 EUR3.59%
  • SANTHERA93.70 CHF2.74%


  • CYTOS0.62 CHF-8.82%
  • CO.DON2.80 EUR-3.78%
  • 4SC4.70 EUR-1.67%


  • 4SC4.70 EUR282.1%
  • WILEX4.17 EUR30.3%
  • SYNGENTA419.20 CHF28.2%


  • CYTOS0.62 CHF-39.2%
  • MEDIGENE9.04 EUR-30.9%
  • BIOTEST75.60 EUR-22.9%


  • WILEX4.17 EUR414.8%
  • CYTOS0.62 CHF342.9%
  • 4SC4.70 EUR327.3%


  • MOLOGEN4.93 EUR-54.4%
  • BIOFRONTERA2.30 EUR-24.1%
  • CO.DON2.80 EUR-23.7%

No liability assumed, Date: 21.05.2015

Current issue

All issues